Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

'A new era of drug discovery’: Company develops drug using AI

For the first time, a company has discovered a drug target and corresponding candidate using artificial intelligence (AI).

26 Sep 2019

Streamlining the compound ordering process for life scientists in the US

Molport has announced its expansion into the US with the opening of MolPort Inc., which will streamline the compound ordering process for US customers.

25 Sep 2019

Scientists move one step closer to discovering the causes of immune diseases

Scientists are one step closer to discovering the causes of immune diseases such as asthma, multiple sclerosis and arthritis

23 Sep 2019

Version of an antibiotic drug extends survival in mice with lethal pediatric brain tumors

Versions of an antibiotic drug called DON first isolated from soil bacteria more than 60 years ago have shown promising signs of extending survival in mice models of especially lethal pediatric brain tumors marked by the high expression of a cancer-causing gene known as the MYC oncogene, according to results of two studies from researchers at the Johns Hopkins Kimmel Cancer Center.

23 Sep 2019

Scientists identify new family of drugs which could combat prostate cancer

A new family of drugs which inhibit the activity of a protein associated with prostate and other cancers has been reported by scientists from the University of Bath.

20 Sep 2019

Authenticated mast cells successfully developed from hematopoietic stem cells

Mast cells are critically involved in immunity and immune disorders. However, they are rarely cultured ex vivo for experimental manipulation because of the difficulty in isolating useful numbers and limitations related to 2D culture.

20 Sep 2019

New AI-guided robotic platform for automation of synthetic biological molecules

A cross-disciplinary team of MIT researchers have published details of an artificial intelligence (AI) guided robotic platform for flow synthesis of small molecule organic compounds. The paper appeared in the August 9, 2019 issue of Science.

17 Sep 2019

Accelerating drug discovery process to help patients

An international research team has developed a new strategy that can predict the potential clinical implications of new therapeutic compounds based on simple cellular responses.

15 Sep 2019

Children's Tumor Foundation harnesses interest in rare disease research through NF Innovation Week

Neurofibromatosis, a genetic disorder that causes tumors to grow on nerves throughout the body and which affects 1 in 3,000 people - that's over 2.5 million worldwide - has no cure and few workable treatment options.

15 Sep 2019

Lundbeck chooses Discngine’s 3decision platform for handling complex protein-ligand 3D structure data

Discngine, a software company specialized in developing applications for life sciences research, today announces that Lundbeck has selected its proprietary 3decision collaborative platform to manage the pharma company’s structural knowledge related to protein and ligand 3D structures.

5 Sep 2019

NIH trial aims to improve drug discovery for ischemic stroke

The NIH has announced it will fund a nationwide preclinical trial focusing on robust testing of new treatments for acute ischemic stroke.

4 Sep 2019

Mount Sinai researchers discover drug resistance signature in Crohn's disease

By mapping out more than 100,000 immune cells in patients with Crohn's disease, Mount Sinai researchers have discovered a signature of cells that are involved in a type of the disease that does not respond to treatment, according to a study published in Cell in August.

29 Aug 2019

Potential drug could revolutionize the treatment of neurological conditions

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may prevent neuronal death through glucose metabolism modification in stressed neurons.

28 Aug 2019

U of T scientists create antibodies with enormous potential for regenerative medicine

Our body makes antibodies to fight infections. But the synthetic versions of these molecules could hold the key to stimulating the body's ability to regenerate.

27 Aug 2019

NIH announces new round of funding for Research Centers in Minority Institutions

The National Institute on Minority Health and Health Disparities, part of the National Institutes of Health, has funded three new awards and renewed the awards of eight institutions previously funded under the Research Centers in Minority Institutions Specialized Centers program.

26 Aug 2019

Individually packed sterile assay microplates for optimized tissue culture cell growth

Porvair Sciences announces its complete range of Krystal (TM) clear bottomed assay microplates is now available individually packed and sterilized for optimized tissue culture cell growth or non-sterile for assay development.

From Porvair Sciences Limited 26 Aug 2019

Biosero’s GBG Batch Planner accelerates lab productivity, maximizes use of high-value equipment

Biosero, Inc. released the GBG Batch Planner today, a plug-in for its Green Button Go Automation Scheduling Software Suite that accelerates lab productivity by automating schedules for high-value lab equipment.

From Biosero Inc. 26 Aug 2019

Head-to-head comparison of three breast cancer drugs reveals important differences

Every year, more than 250,000 women in the U.S. are diagnosed with breast cancer. When detected early, patients with the most common form--which tests positive for hormone receptors (HR+) and negative for the HER2 receptor--usually respond well to treatment.

23 Aug 2019

FDA clears its IND for new immunotherapeutic for treating prostate cancer

Calibr, the drug development division of Scripps Research, announced today that the U.S. Food and Drug Administration has cleared its investigational new drug application for CCW702, a novel immunotherapeutic for the treatment of patients with metastatic castration-resistant prostate cancer.

21 Aug 2019

Northwestern scientists receive $3.1 million grant to investigate drug therapies for ALS

Two Northwestern University scientists have received a $3.1 million grant from the National Institute on Aging to collaborate and investigate drug therapies for amyotrophic lateral sclerosis.

18 Aug 2019